Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma

Journal of Radiation Research

Volumn 51, Issue 5, 2010, Pages 589-594

  Shirai, Katsuyuki ^a   Suzuki, Yoshiyuki ^a   Okamoto, Masahiko ^a   Wakatsuki, Masaru ^a   Noda, Shin ei ^a   Takahashi, Takeo ^b   Ishiuchi, Shogo ^c   Hasegawa, Masatoshi ^a   Nakazato, Yoichi ^a   Nakano, Takashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIOTHERAPY; SURGERY;

ANAPLASTIC ASTROCYTOMA; BRAIN TUMORS; COMBINED THERAPY; DIFFERENTIAL DIAGNOSIS; OLIGOASTROCYTOMA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSTOPERATIVE RADIOTHERAPY; PROGNOSTIC FACTORS; WORLD HEALTH ORGANIZATION;

TUMORS;

EID: 77958555624     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.10055     Document Type: Article

References (32)

1. Mahaley MS, et al (1989) National survey of patterns of care for brain-tumor patients. J Neurosurg 71: 826-836.
2. Jeremic B, et al (2004) Combined treatment modality for ana-plastic oligodendroglioma and oligoastrocytoma: a 10-year update of a phase II study. Int J Radiat Oncol Biol Phys 59: 509-514.
3. Winger MJ, Macdonald DR and Cairncross JG (1989) Suprat-entorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71: 487-493.
4. Boiardi A, et al (1997) Advantage of treating anaplastic glio-mas with aggressive protocol combining chemotherapy and radiotherapy. J Neurooncol 34: 179-185.
5. Wick W, et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with pro-carbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880.
6. Van den bent MJ (2007) Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 25: 1089-1109.
7. Glass J, et al (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741-745.
8. Tortosa A, et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97: 1063-1071.
9. Kim L, et al (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and IV oligoastrocytomas. J Neurosurg 85: 602-607.
10. Cairncross JG (1994) Aggressive oligodendroglioma: a chemosensitive tumor. Recent Results Cancer Res 135: 127- 133.
11. Cairncross JG and Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360-364.
12. Miller CR, et al (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24: 5419-5426.
13. Shaw EG, et al (1997) Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 31: 273-278.
14. Krouwer HG, et al (1997) Oligoastrocytomas: a clinicopatho-logical study of 52 cases. J Neruooncol 33: 223-228.
15. Kyritsis AP, et al (1993) The treatment of anaplastic oligoden-drogliomas and mixed gliomas. Neurosurgery 32: 365-371.
16. Cairncross G, et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714.
17. Coons SW, et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393.
18. Kros JM, et al (2007) Panel review of anaplastic oligodendro-glioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66: 545-551.
19. Marie Y, et al (2001) OLIG2 as a specific marker of oligo-dendroglial tumour cells. Lancet 358: 298-300.
20. Ueki K, et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8: 196-201.
21. Idbaih A, et al (2008) BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 122: 1778-1786.
22. Idbaih A, et al (2008) Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro Oncol 10: 540-547.
23. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta- analysis of individual patient data from 12 randomised trial. Lancet 359:1011-1018.
24. Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518.
25. Van den Bent MJ, et al (2006) Adjuvant procarbazine, lomus-tine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligoden-drogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722.
26. Reid JM, et al (1997) Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3: 2393-2398.
27. Stupp R, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
28. Chinot OL, Honore S and Dufour H (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligoden-drogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455.
29. Yung WK, et al (1999) Multicenter phase II trial of temozo-lomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771.
30. Mikkelsen T, et al (2009) Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92: 57-63.
31. Vogelbaum MA, et al (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 11: 167- 175.
32. Wen PY and Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.